Renal centers in Italy and Russia collaborate to decrease disease burden Featured

RemuzziThis June, Past ISN President Giuseppe Remuzzi lectured at the Moscow City Nephrology Center. He updated the audience on the latest understandings of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) and looked at new insights into defining, treating and the pathophysiology of membranoproliferative glomerulonephritis (MPGN).

“It was a unique opportunity get an expert view from the person who implemented this term in nephrology,” adds Boris Bikbov, Associate Professor and Chair of Nephrology at the Moscow State University of Medicine and Dentistry.

Audience moscow srcThe Mario Negri Institute for Pharmacological Research in Bergamo, Italy, has led research on these syndromes and recently helped to implement a novel diagnostic test for measuring complement C5b-9 complex activity in the solid phase. This provides the crucial information to define the pathophysiological state of the complement activation and adjusting treatment in HUS.

Prof. Remuzzi also discussed with Dr. Boris Bikbov, Prof. Natalia Tomilina, and other representatives of the Russian nephrology community the current progress and future plans for the ISN Sister Renal Center (SRC) partnership, as well as certain aspects of diagnostic and treatment facilities in Russia.

The ISN Sister Renal Center partnership between the Mario Negri Institute for Pharmacological Research and Moscow City Nephrology Center was established in 2009. It has offered valuable training to physicians and nurses.

Remuzzi audience src moscowBikbov adds: “The collaboration between our centers has also helped in the global improvement of prevention, detection, management and awareness of Chronic Kidney Disease and Acute Kidney Injury.”

Experts from both centers have played a key role in the Global Burden of Disease, Injuries and Risk Factors Study in the field of modelling the global epidemiology estimates for the burden of Chronic Kidney Disease and Acute Kidney Injury. The important GBD results for worldwide CKD estimates have already been published in The Lancet. In collaboration with the Institute of Health Metrics and Evaluation in Seattle (USA) they also aim to produce more detailed estimates of CKD burden and its global relationships with cardiovascular diseases, as well as worldwide AKI burden.

To find out more about the ISN Programs and the ISN Sister Renal Center Program, CLICK HERE. Deadline for applications is October 1st, 2015.

Read 958 times

Scroll to Top